Switch theme
Sign up to access all valuation multiples
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.
2007
n/a
LTM Revenue $3.3M
LTM EBITDA -$8.2M
$4.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recce Pharmaceuticals has a last 12-month revenue of $3.3M and a last 12-month EBITDA of -$8.2M.
In the most recent fiscal year, Recce Pharmaceuticals achieved revenue of n/a and an EBITDA of -$10.4M.
Recce Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recce Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$8.0M | -$10.4M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$6.9M | -$8.2M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Recce Pharmaceuticals's stock price is AUD 0 (or $0).
Recce Pharmaceuticals has current market cap of AUD 8.4M (or $5.3M), and EV of AUD 7.2M (or $4.5M).
See Recce Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5M | $5.3M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Recce Pharmaceuticals has market cap of $5.3M and EV of $4.5M.
Recce Pharmaceuticals's trades at 1.4x LTM EV/Revenue multiple, and -0.6x LTM EBITDA.
Analysts estimate Recce Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Recce Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | XXX | XXX |
| P/E | -0.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRecce Pharmaceuticals's NTM/LTM revenue growth is -35%
Recce Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Recce Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Recce Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Recce Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recce Pharmaceuticals acquired XXX companies to date.
Last acquisition by Recce Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Recce Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Recce Pharmaceuticals founded? | Recce Pharmaceuticals was founded in 2007. |
| Where is Recce Pharmaceuticals headquartered? | Recce Pharmaceuticals is headquartered in Australia. |
| Is Recce Pharmaceuticals publicy listed? | Yes, Recce Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Recce Pharmaceuticals? | Recce Pharmaceuticals trades under RCE ticker. |
| When did Recce Pharmaceuticals go public? | Recce Pharmaceuticals went public in 2016. |
| Who are competitors of Recce Pharmaceuticals? | Similar companies to Recce Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Recce Pharmaceuticals? | Recce Pharmaceuticals's current market cap is $5.3M |
| What is the current revenue of Recce Pharmaceuticals? | Recce Pharmaceuticals's last 12-month revenue is $3.3M. |
| What is the current EBITDA of Recce Pharmaceuticals? | Recce Pharmaceuticals's last 12-month EBITDA is -$8.2M. |
| What is the current EV/Revenue multiple of Recce Pharmaceuticals? | Current revenue multiple of Recce Pharmaceuticals is 1.4x. |
| What is the current EV/EBITDA multiple of Recce Pharmaceuticals? | Current EBITDA multiple of Recce Pharmaceuticals is -0.6x. |
| Is Recce Pharmaceuticals profitable? | Yes, Recce Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
